Armen Shanafelt, Ph.D.
Armen Shanafelt, Ph.D., is a general partner at Lilly Ventures. Prior to joining Lilly Ventures in 2009, he had over 24 years of experience in the pharmaceutical, biotechnology and diagnostic businesses. Dr. Shanafelt serves as a director on the boards of Aeglea Biotherapeutics (AGLE; chairman), Aileron Therapeutics, Protagonist Therapeutics, Sutro Biopharma, Surface Oncology and Symic Biomedical (chairman), and sits on the advisory board for the University of Texas System Horizon Fund. He is a Kauffman Fellow (Class 14). He received his bachelor’s degree in chemistry and physics from Pacific Lutheran University and his doctorate degree in chemistry from the University of California, Berkeley, and completed his postdoctoral work at DNAX Research Institute.